(RS)-rhododendrol 2-O-β-D-glucopyranoside | 168038-86-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (RS)-rhododendrol 2-O-β-D-glucopyranoside
• 英文别名: betuloside；[(Ξ)-3-(4-hydroxy-phenyl)-1-methyl-propyl]-β-D-glucopyranoside；[(Ξ)-3-(4-Hydroxy-phenyl)-1-methyl-propyl]-β-D-glucopyranosid；Rhododendrin；(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[4-(4-hydroxyphenyl)butan-2-yloxy]oxane-3,4,5-triol
• CAS: 168038-86-6
• 化学式: C₁₆H₂₄O₇
• 分子量: 328.362
• InChiKey: KLLYDTMVSVIJEH-YLHHEPAUSA-N

物化性质

• 沸点：
  571.8±50.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  120
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (RS)-rhododendrol 2-O-β-D-glucopyranoside 在 acid 作用下， 生成 4-(对羟基苯基)-2-丁醇
  参考文献：
  名称：

  Bioconversion of rhododendrol by Acer nikoense

  摘要：

  Callus derived from Acer nikoense tissue contained the same compounds as the parent plants, but (+)-rhododendrol, which has hepatoprotective activity, was not detected in the methanol extract of the callus. Cells in suspension culture converted (RS)-rhododendrol into (RS)-rhododendrol 2-O-beta-D-glucopyranoside and (R)-rhododendrol 2-O-beta-D-xylopyranosyl-(1 --> 6)-beta-D-glucopyranoside. This is the first time that the latter compound has been isolated from a natural source.

  DOI：

  10.1016/0031-9422(95)00102-d
• 作为产物：
  描述：

  (R)-rhododendrol 2-O-β-D-xylopyranosyl-(1->6)-β-D-glucopyranoside 在 三氟乙酸 作用下， 以 水 为溶剂， 反应 2.0h， 生成 D-吡喃木糖 、 D-葡萄糖 、 (RS)-rhododendrol 2-O-β-D-glucopyranoside
  参考文献：
  名称：

  Bioconversion of rhododendrol by Acer nikoense

  摘要：

  Callus derived from Acer nikoense tissue contained the same compounds as the parent plants, but (+)-rhododendrol, which has hepatoprotective activity, was not detected in the methanol extract of the callus. Cells in suspension culture converted (RS)-rhododendrol into (RS)-rhododendrol 2-O-beta-D-glucopyranoside and (R)-rhododendrol 2-O-beta-D-xylopyranosyl-(1 --> 6)-beta-D-glucopyranoside. This is the first time that the latter compound has been isolated from a natural source.

  DOI：

  10.1016/0031-9422(95)00102-d

文献信息

• Production par bioconversion de cétone framboise
  申请人：BFA LABORATOIRES

  公开号：EP0707072A1

  公开（公告）日：1996-04-17

  L'invention concerne un procédé de fabrication, par voie enzymatique, de 4-(4'-hydroxyphényl)butan-2-one ("cétone framboise") caractérisé par la mise en contact du 4-(4'-hydroxyphényl)butan-2-ol avec une source d'enzyme ayant une activité d'alcool déshydrogénase. Le produit de l'invention est utilisé comme substance naturelle d'arôme dans des produits alimentaires, cosmétiques, pharmaceutiques ou dans des parfums.

  本发明涉及用酶法制造 4-(4'-羟基苯基)丁-2-酮（"覆盆子酮"）的工艺，其特征是使 4-(4'-羟基苯基)丁-2-醇与具有醇脱氢酶活性的酶源接触。 本发明的产品可用作食品、化妆品、药品或香水中的天然调味物质。
• PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF BONE DISEASE, FUNCTIONAL FOOD OR HEALTH FOOD COMPRISING THE COMPOSITION, AND PHARMACEUTICAL PREPARATION COMPRISING THE COMPOSITION AS ACTIVE INGREDIENT
  申请人：Akihisa, Toshihiro

  公开号：EP2050442A1

  公开（公告）日：2009-04-22

  The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.)

  本发明提供了一种用于预防和/或治疗骨病的高安全性药物组合物、由其组成的药物制剂、由其组成的保健食品、由其组成的功能性食品。由于本发明包含下式（I）所示的芳基庚烷类化合物及其衍生物，因此能够预防和/或治疗骨病。 (在式(I)中，R1和R5是选自氢原子、碳原子数为1至3的烷基、单糖和二糖的官能团；R2、R3和R4是选自氢原子、氧原子、碳原子数为1至3的烷基、单糖和二糖的官能团；R5可与另一芳基的庚基在元位置上结合形成环)。
• Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient
  申请人：Akihisa, Toshihiro

  公开号：EP2407160A1

  公开（公告）日：2012-01-18

  The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.)

  本发明提供了一种用于预防和/或治疗骨病的高安全性药物组合物、由其组成的药物制剂、由其组成的保健食品、由其组成的功能性食品。由于本发明包含下式（I）所示的芳基庚烷类化合物及其衍生物，因此能够预防和/或治疗骨病。 (在式(I)中，R1和R5是选自氢原子、碳原子数为1至3的烷基、单糖和二糖的官能团；R2、R3和R4是选自氢原子、氧原子、碳原子数为1至3的烷基、单糖和二糖的官能团；R5可与另一芳基的庚基在元位置上结合形成环)。
• Methods of treatment using recombinant oxalate oxidase
  申请人：NEXTTOBE AB

  公开号：US10266811B2

  公开（公告）日：2019-04-23

  Novel oxalate oxidases are provided, which have suitable oxalate degrading activity near physiological pH (7.4). The properties of these OxOx make them potential drug candidates for use in reducing oxalate concentration in patients suffering from excess of oxalate. Especially due to the high activity at physiological pH, the OxOx's are suitable drug candidates for parenteral administration, i.e. to reduce the oxalate concentration in the plasma.

  本研究提供了新型草酸盐氧化酶，它们在生理 pH 值（7.4）附近具有适当的草酸盐降解活性。这些 OxOx 的特性使它们成为潜在的候选药物，可用于降低草酸盐过量患者体内的草酸盐浓度。特别是由于在生理 pH 值下具有高活性，OxOx 是适合肠外给药的候选药物，即用于降低血浆中的草酸盐浓度。
• Polyhipes by interfacial step-growth polymerization
  申请人：Technion Research & Development Foundation Limited

  公开号：US10851218B2

  公开（公告）日：2020-12-01

  A polyHIPE-templated composition-of-matter afforded by interfacial polymerization, comprising a polymer of alternating residues of hydrophobic and hydrophilic monomers. The described composition-of-matter is characterized by an open-, quasi-closed- or a truly closed-cell microstructure, whereas the latter is capable of non-releasably or releasably encapsulating an organic or aqueous composition therein for extended periods of time, as well as various uses thereof.

  一种通过界面聚合法获得的聚 HIPE 模板物质组合物，由疏水单体和亲水单体交替残留的聚合物组成。所述物质组合物的特点是具有开孔、准闭孔或真正闭孔的微观结构，而后者能够以不可释放或可释放的方式将有机或水性组合物长时间封装在其中，并具有多种用途。